Eribulin - Eisai Co Ltd

Drug Profile

Eribulin - Eisai Co Ltd

Alternative Names: B-1939; B-1939 mesylate; E-7386; E-7389; ER-086526; Eribrin; Eribulin mesylate; Halaven; NSC-707389

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eisai Co Ltd; Harvard University
  • Developer Asan Medical Center; Eisai Co Ltd; Emory University; Merck & Co; National Cancer Institute (USA); PIQUR Therapeutics
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Furans; Ketones; Macrocyclic compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Soft tissue sarcoma
  • Phase III Non-small cell lung cancer
  • Phase II Ewing's sarcoma; Haemangioendothelioma; Haemangiosarcoma
  • Phase I/II Bladder cancer; Solid tumours
  • Discontinued Prostate cancer

Most Recent Events

  • 19 Feb 2018 Phase-II clinical trials in Ewing's Sarcoma (Second-line therapy or greater, In adults, In children, In adolescents, In infants) in USA (IV) (NCT03441360)
  • 16 Feb 2018 Eribulin is still in phase I trials for Solid-tumours (In adolescents, In children, In infants, Refractory metastatic disease, Second-line therapy or greater) in USA
  • 05 Feb 2018 Additional subgroup analyses efficacy and adverse events data from the study 309 phase III trial in Soft tissue sarcoma released by Eisai
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top